Managers / Q1 2021 · view latest →
Foresite Capital Management IV, LLC
CIK 0001704132 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management IV, LLC reported $835M in U.S.-listed holdings across 13 positions for Q1 2021.
The portfolio is heavily concentrated: Kinnate Biopharma alone accounts for 36.1% of reported value.
Compared with Q4 2020, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 88.2% · $737M
- Other · 11.8% · $98M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Pharvaris N.V. | NEW | +3.26M | 3.26M | +$91M | $91M |
| Decibel Therapeutics, Inc. | NEW | +297.7K | 297.7K | +$3M | $3M |
| ACRSAclaris Therapeutics, Inc. | ADDED | +2.45M | 3.40M | +$80M | $86M |
| Generation Bio Co. | SOLD OUT | −857.9K | 0 | −$24M | $0 |
| PCVXVaxcyte, Inc. | SOLD OUT | −465.8K | 0 | −$12M | $0 |
| OLMAOlema Pharmaceuticals, Inc. | TRIMMED | −425.0K | 393.0K | −$26M | $13M |
| NRIXNurix Therapeutics, Inc. | TRIMMED | −1.11M | 1.24M | −$39M | $39M |
| CYTKCytokinetics Incorporated | TRIMMED | −554.1K | 881.9K | −$9M | $21M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | Kinnate Biopharma Inc. | COM | 36.10% | $301M | 9.67M |
| 2 | Pharvaris N.V. | COM | 10.93% | $91M | 3.26M |
| 3 | ACRSAclaris Therapeutics, Inc.history → | COM | 10.26% | $86M | 3.40M |
| 4 | KROSKeros Therapeutics, Inc.history → | COM | 10.19% | $85M | 1.38M |
| 5 | RLAYRelay Therapeutics, Inc.history → | COM | 8.86% | $74M | 2.14M |
| 6 | ALXOALX Oncology Holdings Inc.history → | COM | 6.94% | $58M | 785.9K |
| 7 | KURAKura Oncology, Inc.history → | COM | 6.26% | $52M | 1.85M |
| 8 | NRIXNurix Therapeutics, Inc.history → | COM | 4.61% | $39M | 1.24M |
| 9 | CYTKCytokinetics Incorporatedhistory → | COM | 2.46% | $21M | 881.9K |
| 10 | OLMAOlema Pharmaceuticals, Inc.history → | COM | 1.56% | $13M | 393.0K |
| 11 | Cymabay Therapeutics, Inc. | COM | 0.97% | $8M | 1.79M |
| 12 | Therapeutics Acquisition Corp | COM CL A | 0.44% | $4M | 350.0K |
| 13 | Decibel Therapeutics, Inc. | COM | 0.41% | $3M | 297.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $237M | 8 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $230M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $183M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $124M | 6 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $111M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $109M | 4 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $153M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $149M | 4 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $198M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $198M | 5 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $180M | 7 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $203M | 7 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $193M | 8 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $234M | 8 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $311M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $371M | 8 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $357M | 9 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $486M | 9 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $679M | 12 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $740M | 13 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $835M | 13 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $921M | 13 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $443M | 15 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $205M | 12 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $81M | 11 | May 28, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2019 | $232M | 14 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $309M | 19 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $354M | 22 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $278M | 16 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.